Quarterly ResultMay 8, 2026, 06:46 AM
Artiva Biotherapeutics Q1 Net Loss $(23.5M); Cash $86.8M
AI Summary
Artiva Biotherapeutics reported an increased net loss for Q1 2026, reaching $(23.5) million, up from $(20.3) million in Q1 2025. The company's cash, cash equivalents, and investments decreased to $86.8 million as of March 31, 2026, from $108.0 million at December 31, 2025. Artiva continues to focus on developing NK cell-based therapies, with its lead candidate AlloNK in clinical development, and anticipates needing additional funding beyond Q2 2027 to support its operations.
Key Highlights
- Net loss increased to $(23.5) million in Q1 2026 from $(20.3) million in Q1 2025.
- Net loss per share was $(0.95) in Q1 2026, compared to $(0.83) in Q1 2025.
- Research and development expenses rose to $19.3 million in Q1 2026 from $17.1 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $86.8 million as of March 31, 2026.
- Net cash used in operating activities was $(21.0) million in Q1 2026.
- Accumulated deficit reached $(354.1) million as of March 31, 2026.
- Existing funds are expected to last into Q2 2027, requiring future additional funding.